{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T21:10:44Z","timestamp":1648933844943},"reference-count":4,"publisher":"American Medical Association (AMA)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,5,4]]},"DOI":"10.1001\/jama.2021.2780","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T15:00:57Z","timestamp":1620140457000},"page":"1791","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer"],"prefix":"10.1001","volume":"325","author":[{"given":"Feng","family":"Du","sequence":"first","affiliation":[{"name":"The VIPII Gastrointestinal Cancer Division of Medical Department, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Yuan","sequence":"additional","affiliation":[{"name":"National Cancer Centre\/National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"1","key":"jle210021r1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2020.23370","article-title":"Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial.","volume":"325","author":"Wang","year":"2021","journal-title":"JAMA"},{"issue":"16","key":"jle210021r2","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1200\/JCO.19.02474","article-title":"Adjuvant capecitabine with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (CBCSG010): an open-label, randomized, multicenter, phase III trial.","volume":"38","author":"Li","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"jle210021r3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1200\/JCO.19.00904","article-title":"Phase III trial of adjuvant capecitabine after standard neo-\/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM\/2003-11_CIBOMA\/2004-01).","volume":"38","author":"Lluch","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"jle210021r4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nrclinonc.2016.64","article-title":"Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.","volume":"13","author":"Bocci","year":"2016","journal-title":"Nat Rev Clin Oncol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2779557\/jama_du_2021_le_210021_1620138056.05225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T15:01:01Z","timestamp":1620140461000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2779557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":4,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,5,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2021.2780","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,4]]}}}